v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NON-CONTROLLING INTERESTS AND EQUITY - USD ($)
shares in Thousands, $ in Millions
Total
Redeemable Non-Controlling Interests
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Non-Redeemable Non-Controlling Interests
Beginning Balance at Dec. 31, 2019   $ 311          
Increase (Decrease) in Temporary Equity [Roll Forward]              
Distributions to non-controlling interests $ (4) (3)         $ (4)
Net income (loss)   (18)          
Ending Balance at Mar. 31, 2020   290          
Beginning balance (in shares) at Dec. 31, 2019     1,716,681        
Beginning balance at Dec. 31, 2019 14,872   $ 0 $ 30,739 $ (187) $ (16,362) 682
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options (in shares)     4,359        
Exercise of stock options 14     14      
Stock-based compensation 285     285      
Issuance of common stock for settlement of RSUs (in shares)     8,917        
Shares withheld related to net share settlement (in shares)     (107)        
Shares withheld related to net share settlement (3)     (3)      
Unrealized gain on investments in available-for-sale securities, net of tax (60)       (60)    
Foreign currency translation adjustment (148)       (148)    
Distributions to non-controlling interests (4) (3)         (4)
Net loss (2,928)         (2,936)  
Net loss             8
Ending balance (in shares) at Mar. 31, 2020     1,729,850        
Ending balance at Mar. 31, 2020 12,028   $ 0 31,035 (395) (19,298) 686
Beginning Balance at Dec. 31, 2019   311          
Ending Balance at Jun. 30, 2020   282          
Beginning balance (in shares) at Dec. 31, 2019     1,716,681        
Beginning balance at Dec. 31, 2019 14,872   $ 0 30,739 (187) (16,362) 682
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Unrealized gain on investments in available-for-sale securities, net of tax (52)            
Foreign currency translation adjustment (405)            
Ending balance (in shares) at Jun. 30, 2020     1,745,957        
Ending balance at Jun. 30, 2020 10,239   $ 0 31,267 (644) (21,073) 689
Beginning Balance at Mar. 31, 2020   290          
Increase (Decrease) in Temporary Equity [Roll Forward]              
Derecognition of non-controlling interests upon divestiture (5) (3)         (5)
Net income (loss)   (5)          
Ending Balance at Jun. 30, 2020   282          
Beginning balance (in shares) at Mar. 31, 2020     1,729,850        
Beginning balance at Mar. 31, 2020 12,028   $ 0 31,035 (395) (19,298) 686
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options (in shares)     3,106        
Exercise of stock options 8     8      
Stock-based compensation 143     143      
Issuance of common stock under the Employee Stock Purchase Plan (in shares)     3,265        
Issuance of common stock under the Employee Stock Purchase Plan 82     82      
Issuance of common stock for settlement of RSUs (in shares)     9,778        
Shares withheld related to net share settlement (in shares)     (42)        
Shares withheld related to net share settlement (1)     (1)      
Derecognition of non-controlling interests upon divestiture (5) (3)         (5)
Unrealized gain on investments in available-for-sale securities, net of tax 8       8    
Foreign currency translation adjustment (257)       (257)    
Net loss (1,767)         (1,775)  
Net loss             8
Ending balance (in shares) at Jun. 30, 2020     1,745,957        
Ending balance at Jun. 30, 2020 10,239   $ 0 31,267 (644) (21,073) 689
Beginning Balance at Dec. 31, 2020   787          
Increase (Decrease) in Temporary Equity [Roll Forward]              
Recognition of non-controlling interest on acquisition   56          
Derecognition of non-controlling interests upon divestiture $ (701) (356)         (701)
Net income (loss)   (14)          
Ending Balance at Mar. 31, 2021   473          
Beginning balance (in shares) at Dec. 31, 2020 1,849,794   1,849,794        
Beginning balance at Dec. 31, 2020 $ 12,967   $ 0 35,931 (535) (23,130) 701
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Reclassification of the equity component of 2025 Convertible Notes to liability upon adoption of ASU 2020-06 (243)     (243)      
Exercise of stock options (in shares)     3,518        
Exercise of stock options 35     35      
Stock-based compensation 287     287      
Issuance of common stock for settlement of Careem Convertible Notes (in shares)     2,872        
Issuance of common stock for settlement of Careem Convertible Notes 158     158      
Issuance of common stock as consideration for acquisitions (in shares)     505        
Issuance of common stock as consideration for acquisitions 28     28      
Issuance of common stock for settlement of RSUs (in shares)     10,924        
Shares withheld related to net share settlement (in shares)     (244)        
Shares withheld related to net share settlement (14)     (14)      
Derecognition of non-controlling interests upon divestiture (701) (356)         (701)
Unrealized gain on investments in available-for-sale securities, net of tax 1,156       1,156    
Foreign currency translation adjustment 33       33    
Net loss (108)         (108)  
Ending balance (in shares) at Mar. 31, 2021     1,867,369        
Ending balance at Mar. 31, 2021 $ 13,598   $ 0 36,182 654 (23,238) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Accounting Standards Update [Extensible List]              
Beginning Balance at Dec. 31, 2020   787          
Ending Balance at Jun. 30, 2021   1,569          
Beginning balance (in shares) at Dec. 31, 2020 1,849,794   1,849,794        
Beginning balance at Dec. 31, 2020 $ 12,967   $ 0 35,931 (535) (23,130) 701
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Unrealized gain on investments in available-for-sale securities, net of tax 1,162            
Foreign currency translation adjustment $ 54            
Ending balance (in shares) at Jun. 30, 2021 1,880,310   1,880,310        
Ending balance at Jun. 30, 2021 $ 14,175   $ 0 35,588 681 (22,094) 0
Beginning Balance at Mar. 31, 2021   473          
Increase (Decrease) in Temporary Equity [Roll Forward]              
Recognition of non-controlling interest on acquisition   76          
Re-measurement of non-controlling interest (1,058) 1,052   (1,058)      
Net income (loss)   (32)          
Ending Balance at Jun. 30, 2021   1,569          
Beginning balance (in shares) at Mar. 31, 2021     1,867,369        
Beginning balance at Mar. 31, 2021 13,598   $ 0 36,182 654 (23,238) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options (in shares)     2,454        
Exercise of stock options 40     40      
Stock-based compensation 282     282      
Reclassification of share-based award liability to additional paid-in capital 4     4      
Issuance of common stock for settlement of Careem Convertible Notes (in shares)     1,352        
Issuance of common stock for settlement of Careem Convertible Notes 74     74      
Issuance of common stock under the Employee Stock Purchase Plan (in shares)     1,710        
Issuance of common stock under the Employee Stock Purchase Plan 67     67      
Issuance of common stock for settlement of RSUs (in shares)     7,480        
Shares withheld related to net share settlement (in shares)     (55)        
Shares withheld related to net share settlement (3)     (3)      
Re-measurement of non-controlling interest (1,058) $ 1,052   (1,058)      
Unrealized gain on investments in available-for-sale securities, net of tax 6       6    
Foreign currency translation adjustment 21       21    
Net loss $ 1,144         1,144  
Ending balance (in shares) at Jun. 30, 2021 1,880,310   1,880,310        
Ending balance at Jun. 30, 2021 $ 14,175   $ 0 $ 35,588 $ 681 $ (22,094) $ 0